Sunday, May 31, 2020

Congratulations to Chia Tai Tianqing Pharmaceutical Group and Janssen for Licensing Agreement

Congratulations to our long-time collaboration partners Chia Tai Tianqing Pharmaceutical Group (CTTQ) and Janssen Pharmaceuticals Inc. for reaching an exclusive license agreement.   Under the agreement, CTTQ grants Janssen rights to develop and commercialize an undisclosed immuno-modulating agent to treat chronic hepatitis B virus (HBV)...

WuXi NextCODE and Fudan Children’s Hospital Partner to Lead Whole Genome Diagnostics for Rare Diseases in China

We are excited to share with you that our wholly owned subsidiary, WuXi NextCODE, has teamed up with Children’s Hospital of Fudan University (CHFU) to take the lead in rare disease diagnosis, care and research in China and offer patients in China world-class testing...

WuXi’s BIO 2015 Recap

The 2015 International BIO Convention in Philadelphia brought together over 15,000 industry leaders from around the world interested in innovation, partnership, and progress in the biotechnology and healthcare industries.  At the convention, WuXi had the opportunity to connect with many of our collaborative partners...

WuXi Discovery Biology Receives “Excellent Partner Award”

We are honored to have received the "Excellent Partner Award" from the Lilly China Research and Development Center (LCRDC) in March 2014.  The award recognizes of the contribution of the WuXi Discovery Biology team, in collaboration with LCRDC, in accelerating key deliveries of a...

WuXi Healthcare Ventures II Closes with Oversubscription

We are pleased to announce that our WuXi Healthcare Ventures (WXHV) has closed a new fund of $290 million WuXi Healthcare Ventures II, L.P., exceeding the initial target of $200 million.  The new fund builds on the successes of its predecessor fund launched in...

Subscribe to our Newsletter

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

INNOVATION THAT MATTERS